PuraPharm International (H.K) Ltd. was founded in Hong Kong
PuraPharm was granted the single formulae research project of CCMG by the State Administration of Traditional Chinese Medicine (SATCM) among 257 pharmaceutical applicants, making us the first Hong Kong-based company in a national pharmaceutical research programme.
PuraPharm was granted the combo formulae research project of concentrated Chinese medicine granules by the State Administration of Traditional Chinese Medicine (SATCM)
Designated by the Ministry of Science and Technology (MST) to conduct quality specification & clinical efficacy studies for combo concentrated Chinese medicine granules as a part of the National Tenth Five-Year Plan
PuraPharm (Nanning) Pharmaceuticals Co. Ltd. was selected as one of the manufacturers of concentrated Chinese medicine granules (CCMG) by the State Food and Drug Administration (SFDA) in recognition of its pioneering role in the field of modernization and internationalization of TCM
(SFDA is the former name of China Food and Drug Administration (CFDA))
PuraPharm became the exclusive CCMG supplier to HK hospitals.
The opening of PuraPharm’s factory in Nanning National High-tech Development Zone in Guangxi
GMP certified by SFDA
Nong’s became the most commonly used TCM brand among Hong Kong Hospitals*
PuraPharm Pharmaceutical Testing Centre passed the CNAS laboratory certification (ISO-17025) – which made PuraPharm the first CFDA-licensed CCMG manufacturer with a testing laboratory which is certified by CNAS in accordance with ISO 17025 standards.
ONCO-Z® coriolus versicolor extract, the sole ingredient of one of our Chinese healthcare products, was verified by USP as dietary supplement ingredient and became the world’s first TCM ingredient verified by the USP. The USP dietary supplement ingredient standards are recognized as one of the strictest quality control standards for assessment of the identity, strength, quality and purity of dietary ingredients.
PuraPharm was certified by Australia’s Therapeutic Goods Administration (TGA), one of the strictest international GMP standards.
PuraPharm obtained funding of “One Hundred Billion Yuan Industry Key Science and Technology Project of Guangxi”, exhibiting PuraPharm’s commitment to the national modernization of medicine.
PuraPharm (Nanning) Pharmaceutical Co. Ltd. was first ranked “Top Five Companies of Proprietary Chinese Medicine Exports 2011”
PuraPharm (Nanning) Pharmaceutical Co. Ltd. advanced and ranked “Top Four Companies of Proprietary Chinese Medicine Exports 2012”
PuraPharm (Nanning) Pharmaceutical Co. Ltd. further advanced and ranked “Top Three Companies of Proprietary Chinese Medicine Exports 2013”
PuraPharm’s Radix Astragali Fomula Granules was verified by the United States Pharmacopoeia (USP) Dietary Ingredient Verification Program
PuraPharm entered into a distribution framework agreement with Sinopharm International, a Hong Kong subsidiary of Sinopharm, which is one of the largest distributors of pharmaceutical and healthcare products in China, to distribute our CCMG products, hence expanding and strengthening our distribution network in China.
Nong’s awarded “Hong Kong Top Brand Awards” issued by the Hong Kong Brand Development Council.
For the fourth consecutive year, PuraPharm (Nanning) Pharmaceutical Co. Ltd. was awarded the “Top Five Companies of Proprietary Chinese Medicine Exports “ (4th Place)”.
PuraPharm Corporation Ltd. was officially listed on the Main Board of the Hong Kong Stocks Exchange on 8 July 2015 (Stock Code: 1498).
PuraPharm established its 30th Nong’s® Chinese Medicine Clinic in Hong Kong.
For the fifth consecutive year, PuraPharm (Nanning) Pharmaceutical Co. Ltd. was awarded the “Top Five Companies of Proprietary Chinese Medicine Exports “ (3rd Place)”.
For the sixth consecutive year, PuraPharm (Nanning) Pharmaceutical Co. Ltd. was awarded the “Top Five Companies of Proprietary Chinese Medicine Exports (3rd Place)”.
PuraPharm was awarded the 2016 Outstanding Import & Export Enterprise Award – Corporate Achievement Award by the Hong Kong Chinese Importers’ & Exporters’ Association.
In November, PuraPharm signed a cooperation agreement with The Chinese University of Hong Kong and Hong Kong Baptist University to develop a new Chinese drug – Ren Shu Chang Le Granules, for the treatment of Irritable Bowel Syndrome. The new drug is the first Hong Kong research project being granted approval for clinical trial by the China Food and Drug Administration (CFDA) on the treatment of Functional Gastrointestinal Disorders.
In March, PuraPharm acquired K’An Herb Company Inc., a company located in California, USA, and principally engaged in the manufacturing of Chinese herbal formulas in the U.S. and sales to distributors and healthcare practitioners in the U.S. and Europe.
In April, PuraPharm acquired the entire equity interest of two companies in Guizhou China, namely Gold Sparkle (Guizhou) HZ Plantation Co., Ltd. and Gold Sparkle (Guizhou) Chinese Medicine Co., Ltd., both owned by Gold Sparkle Plantation Co. Ltd..
In August, PuraPharm acquired SODX Co., Ltd., a Japan-based company that engages in the manufacturing and sales of health food in Japan. SODX’s factory will serve as a pilot factory to transfer the latest technological know-how from Japan to further improve PuraPharm’s products’ quality and production efficiency, and to act as the Group’s new product development centre for business expansion.
PuraPharm’s collaborated project with The Chinese University of Hong Kong and Hong Kong Baptist University on Ren Shu Chang Le Granules (a new Chinese drug for the treatment of Irritable Bowel Syndrome which started in 2016) was granted approval from the China Food and Drug Administration (CFDA) and a Certificate for Clinical Trial and Medicinal Test from the HKSAR Department of Health for the commencement of Phase II clinical trials in Mainland China and Hong Kong.
Nong’s® was awarded “Hong Kong Pharmacy’s Top 20 Most Popular Brand Award” issued by H.K. General Chamber Of Pharmacy.
PuraPharm was awarded the highest honour of “Invotech Firestarters Platinum Award 2019” by Invotech, set up by the Business and Professionals Federation of Hong Kong, for the Group’s achievements in promoting innovation and entrepreneurship in Chinese Medicine.
PuraPharm’s Business & Innovation Centre, a newly established unit commissioned to nurture innovation within the Group, to initiate new products and business, and to steer and drive projects to product launch in the market place was installed.
Nong’s® introduced a new look, and a more convenient and consumer-friendly packaging design, to its range of Nong’s OTC Formula products.
Nong’s® launched a new range of ten OTC Chinese Medicine Capsules products, targeted for consumers’ general relief, overall health and wellbeing.
In February 2020, through the contingency application procedure, Guangxi Zhuang Autonomous Region Food and Drug Administration (“GXFDA”) of the PRC has approved and authorized PuraPharm Nanning to manufacture the Qi Wei Tang(七味湯), Qing Fei Pai Du Tang (清肺排毒湯) and Kang Fu Yi Hao Fang (康復1號方) granules, to be used for the prevention, treatment and recovery of patients who contacted COVID-19 pandemic.
The Group has completed the Rights Issue of HK$98 million net proceeds in March 2020, which further strengthened the capital base and the financial position of the Group.
The Group launched an immunity boosting product, Immuzac+TM, manufactured in Japan, which is an enhanced version of Immuzac® fortified with vitamin C.
The Group launched the Nong’s cinematic brand TVC in March 2020.
The Group has revamped a new research and development centre in Nanning, to enhance the Group’s research and development capability for innovative products development, and preparation for the upcoming national CCMG standardization in China.
The Group has completed phase 1 of the new production facility in Nanning, which composed of 3 modernized warehouse buildings with a total gross floor area of 25,079 square meters in aggregate, as a central hub for supply chain.
In July 2021, PuraPharm’s full range of Nong’s® Chinese medicine clinics launched the 3rd generation cloud-based Chinese Medicine Clinic Management system, the Traditional Chinese Medicine Advisor (TCMA 3.0) offering instant database synchronization and real time patients’ information accessibility, resulting in more timely, more convenient and more accessible Chinese medicine diagnosis and treatment services. The cloud-based consultation and management system is interfaced with a consultation analytics platform enabling evidence-based research and big data analytics of Chinese medicine consultation and prescription cases, providing a brand new experience to traditional Chinese medicine practitioners and users.
In August 2021, the Group changed the Chinese name of the listed company from “培力控股有限公司” to “培力農本方有限公司”.
PuraPharm was awarded the InnoESG Prize Series – ESG Care Prize 2021 by the SocietyNext Foundation, recognizing the Group’s contribution to creating a more sustainable society and a more eco-friendly environment.